Sensyne Health plc announced it has successfully completed the financing announced on 14 January 2022. The financing comprises up to £11.35 million (comprising a first tranche of £6.35 million and an additional tranche of £5 million by mutual consent) and will fund the business through the ongoing Formal Sale Process. Lord Drayson has confirmed his commitment to the Company's mission and its unique ethical business model for the use of anonymised patient data in medical research in partnership with the NHS and health systems world-wide.

He has proposed and the Company has agreed that he will reduce his base salary to £1 per annum while the Loan Notes are outstanding and he has committed to vote for any bid for the Company that results from the Formal Sale Process that is consistent with the Company's mission and maximises value for shareholders or is recommended by the independent Directors.